NASDAQ:BLFS - BioLife Solutions Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$21.99 +0.87 (+4.12 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close$21.99
Today's Range$21.00 - $22.06
52-Week Range$3.10 - $22.86
Volume266,454 shs
Average Volume422,297 shs
Market Capitalization$298.75 million
P/E Ratio-104.71
Dividend YieldN/A
Beta0.38
BioLife Solutions logoBioLife Solutions, Inc. develops, manufactures, and markets patented tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, and delayed-onset cell damage and death. The company offers HypoThermosol FRS, a hypothermic storage and shipping media product to mitigate temperature-induced molecular cell stress responses that occur during chilling and re-warming of biologics, intermediate products, and final cell products intended for research and clinical applications; and CryoStor cryopreservation freeze media products to mitigate temperature-induced molecular cell stress responses during freezing and thawing. It also provides BloodStor freeze media products, such as BloodStor 55-5 and BloodStor 100 for cryopreservation of stem and other cells isolated from umbilical cord and peripheral blood, and bone marrow; and cell thawing media, which offers Dextran and saline for washing cryopreserved cells and tissues to dilute or remove cryoprotectants. In addition, the company provides custom product formulation and packaging services; and contract aseptic manufacturing formulation, filling, and finishing services for liquid media products. It markets its products to the regenerative medicine, bio-banking, and drug discovery markets, including hospital-based stem cell transplant centers, pharmaceutical companies, cord blood and adult stem cell banks, and hair transplant centers, as well as suppliers of cells to the drug discovery, toxicology testing, and diagnostic markets. The company markets and sells its products directly using its sales force, as well as through biolifesolutions.com; and through various regional distributors. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington.

Receive BLFS News and Ratings via Email

Sign-up to receive the latest news and ratings for BLFS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BLFS
CUSIPN/A
Phone425-402-1400

Debt

Debt-to-Equity RatioN/A
Current Ratio7.82
Quick Ratio6.42

Price-To-Earnings

Trailing P/E Ratio-104.71
Forward P/E Ratio314.14
P/E GrowthN/A

Sales & Book Value

Annual Sales$11.02 million
Price / Sales28.24
Cash FlowN/A
Price / CashN/A
Book Value$0.72 per share
Price / Book30.54

Profitability

EPS (Most Recent Fiscal Year)($0.21)
Net Income$-2,510,000.00
Net Margins-13.17%
Return on Equity-18.99%
Return on Assets-15.72%

Miscellaneous

Employees40
Outstanding Shares14,150,000
Market Cap$298.75

BioLife Solutions (NASDAQ:BLFS) Frequently Asked Questions

What is BioLife Solutions' stock symbol?

BioLife Solutions trades on the NASDAQ under the ticker symbol "BLFS."

How were BioLife Solutions' earnings last quarter?

BioLife Solutions Inc (NASDAQ:BLFS) announced its quarterly earnings results on Thursday, March, 8th. The medical equipment provider reported ($0.05) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.04) by $0.02. The medical equipment provider had revenue of $3.13 million for the quarter, compared to analysts' expectations of $3.10 million. BioLife Solutions had a negative return on equity of 18.99% and a negative net margin of 13.17%. View BioLife Solutions' Earnings History.

When is BioLife Solutions' next earnings date?

BioLife Solutions is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for BioLife Solutions.

What price target have analysts set for BLFS?

3 Wall Street analysts have issued 1-year price objectives for BioLife Solutions' shares. Their predictions range from $12.00 to $19.00. On average, they anticipate BioLife Solutions' stock price to reach $15.50 in the next year. This suggests that the stock has a possible downside of 29.5%. View Analyst Ratings for BioLife Solutions.

What is the consensus analysts' recommendation for BioLife Solutions?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioLife Solutions in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of BioLife Solutions' key competitors?

Who are BioLife Solutions' key executives?

BioLife Solutions' management team includes the folowing people:
  • Mr. Michael P. Rice, Pres, CEO & Director (Age 55)
  • Mr. Roderick de Greef, CFO & Sec. (Age 58)
  • Dr. Aby J. Mathew, Chairman of Scientific Advisory Board, Chief Technology Officer and Sr. VP (Age 46)
  • Ms. Karen Foster, VP of Operations (Age 58)
  • Mr. Kevin O'Donnell, VP of Cold Chain Standards, Practices & Compliance

Has BioLife Solutions been receiving favorable news coverage?

News coverage about BLFS stock has been trending somewhat positive on Saturday, Accern reports. The research firm identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. BioLife Solutions earned a media sentiment score of 0.04 on Accern's scale. They also gave news stories about the medical equipment provider an impact score of 47.00 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Who are BioLife Solutions' major shareholders?

BioLife Solutions' stock is owned by a variety of of retail and institutional investors. Top institutional investors include GIRSCHWEILER THOMAS (21.60%), CASDIN CAPITAL, LLC (7.10%), Essex Investment Management Co. LLC (2.09%) and Bank of Montreal Can (0.07%). Company insiders that own BioLife Solutions stock include Andrew G Hinson, Greef Roderick De, Joseph C Schick, Michael Rice, Raymond W Cohen, Thomas Girschweiler and Walter Villiger. View Institutional Ownership Trends for BioLife Solutions.

Which institutional investors are buying BioLife Solutions stock?

BLFS stock was acquired by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC and Bank of Montreal Can. View Insider Buying and Selling for BioLife Solutions.

How do I buy shares of BioLife Solutions?

Shares of BLFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioLife Solutions' stock price today?

One share of BLFS stock can currently be purchased for approximately $21.99.

How big of a company is BioLife Solutions?

BioLife Solutions has a market capitalization of $298.75 million and generates $11.02 million in revenue each year. The medical equipment provider earns $-2,510,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. BioLife Solutions employs 40 workers across the globe.

How can I contact BioLife Solutions?

BioLife Solutions' mailing address is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. The medical equipment provider can be reached via phone at 425-402-1400 or via email at [email protected]


MarketBeat Community Rating for BioLife Solutions (NASDAQ BLFS)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  130 (Vote Outperform)
Underperform Votes:  74 (Vote Underperform)
Total Votes:  204
MarketBeat's community ratings are surveys of what our community members think about BioLife Solutions and other stocks. Vote "Outperform" if you believe BLFS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLFS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.